Answers are grounded in this paper and cite their sources.
Doping control for anabolic androgenic steroids (AASs) must separate endogenous physiology from exogenous administration when the same molecular entities occur on both sides of the boundary. This Critical Review evaluates analytical strategies for that source-attribution problem, with emphasis on urinary steroid profiling, longitudinal interpretation, compound-specific isotope ratio mass spectrometry, intact phase-II metabolites, alternative matrices, high-resolution mass spectrometry (HRMS), and data-driven evidence integration. Current practice relies on a staged logic: routine steroid-profile measurements define marker behavior, the steroidal module of the Athlete Biological Passport (ABP) evaluates individual changes, and gas chromatography-combustion-isotope ratio mass spectrometry (GC-C-IRMS) supplies orthogonal source evidence when pseudo-endogenous steroids or atypical profiles require confirmation. UDP-glucuronosyltransferase 2B17 (UGT2B17) deletion, sex, menstrual-cycle phase, pregnancy, medication, and sample degradation can alter marker concentrations and ratios. Intact conjugates, dried blood spots (DBS), HRMS metabolite discovery, and statistical tools can provide additional evidence, but their performance depends on validation for the relevant matrix and administration scenario. The most defensible strategy is therefore a tiered framework that combines longitudinal interpretation, source-specific chemical evidence, and expert review.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: